The Work We Fund

Funded projects
1,250+
Men's Health Partners
20
Countries
20
We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact.
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programs
Mental health and suicide prevention
“The number of men taking their own lives around the world is one of the biggest challenges of our time. Movember is working to ensure all men and boys look after their mental health and are comfortable to seek help when they’re struggling.”
Brendan Maher, Global Director, Mental Health and Suicide Prevention.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programs.

Movember-PA Research Foundation Research Acceleration Award

Movember Funding to Date

AUD 250,000

What we seek to achieve

The award aims to accelerate the development of prostate cancer biomedical research projects previously funded by Movember towards the next stage of clinical translation, with the hope that men with prostate cancer will benefit from the research outcomes sooner.

Country
Australia
Co-funded
Princess Alexandra Research Foundation AUD 250,000
Implemented by
Movember
Project start date
October 2021
Project Status
In progress

About the project

Androgen targeted therapies (ATT) are the primary treatment for prostate cancer that has spread outside of the prostate gland, however, prostate tumours adapt to survive by activation of predictable androgen repressed genes that promote alternative tumour growth and survival pathway. 

Previous research by the team (Movember Revolutionary Team Award) identified and characterised a number of novel therapeutic targets, including NRP1 and LEPR, which have been validated to play a role in treatment resistance to ATT and could be successfully targeted with highly specific therapeutic agents. 

This new award will seek to further investigate treatment response and treatment resistance of these agents using PDX models with in depth molecular and tissue characterisation to inform the future clinical translation of these novel therapeutics.

>
Page 1 of 29